In contrast to effects in the fetal membranes and AF, TNF blockade did not decrease mRNA for inflammatory mediators or Connexin-43 in the uterus (Supplementary Figure 11), suggesting that effect of Adalimumab is limited to the feto-maternal interface. The gene discussed is TNF; the disease is atrial fibrillation.